Free Trial
NASDAQ:GNCA

Genocea Biosciences (GNCA) Stock Price, News & Analysis

Genocea Biosciences logo

About Genocea Biosciences Stock (NASDAQ:GNCA)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
83,499 shs
Market Capitalization
$6,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

Remove Ads
Receive GNCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat's FREE daily newsletter.

GNCA Stock News Headlines

Genocea Biosciences (NASDAQ:GNCA) Now Covered by StockNews.com
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Genocea Biosciences Inc GNCAQ
GNCAQ Genocea Biosciences, Inc.
Genocea Biosciences, Inc. (GNCA)
GRPN, GNCA and LAB among mid-day movers
See More Headlines

GNCA Stock Analysis - Frequently Asked Questions

Genocea Biosciences, Inc. (NASDAQ:GNCA) announced its quarterly earnings data on Wednesday, October, 27th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.15. The biotechnology company earned $1.64 million during the quarter.

Shares of GNCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Genocea Biosciences investors own include Hawkins (HWKN), Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW) and Micron Technology (MU).

Company Calendar

Last Earnings
10/27/2021
Today
4/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GNCA
Employees
70
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-33,200,000.00
Pretax Margin
-1,946.15%

Debt

Sales & Book Value

Annual Sales
$1.91 million
Price / Cash Flow
N/A
Book Value
$0.47 per share
Price / Book
N/A

Miscellaneous

Free Float
57,788,000
Market Cap
$6,000.00
Optionable
Not Optionable
Beta
1.61

Social Links

7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:GNCA) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners